What do we do?
At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Diagnostic Network solution for the development and commercialisation of precision medicine diagnostics. The Company, listed on the AIM Market of the London Stock Exchange, has created commercially useful data sets for every precision medicine that has come to market. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500+ labs in 53 countries
What is precision medicine?
Precision medicines (or therapies) are a class of drug tailored to individual patient groups dependent on molecular or genetic factors of the individual. Today, they are used for treatment in oncology as well as other disease areas such as multiple sclerosis and rheumatoid arthritis. The increasing use of precision medicines results from the fact that some drugs have demonstrated significant positive clinical results in some patients but have been shown to be less effective or less safe across the entire patient population.
Who are the key players in precision medicine?
Growth in the precision medicine market is evident, with major pharma companies such as AstraZeneca confirming that approximately 90 per cent of their clinical development pipeline is currently driven by precision therapeutics. This growth is being led by technological advances in genetics and improved understanding in molecular diagnostic techniques, enabling better prospects of the successful development of precision therapeutics. Leading pharma companies working in precision medicine include Novartis, Roche/Genentech, AstraZeneca, Pfizer, BMS, Merck and Amgen. Given the specific nature of precision therapeutics, the successful roll-out of these medicines by a pharmaceutical company is increasingly reliant on having effective and widespread testing available for doctors and patients from launch.
Where does Diaceutics fit in this market?
Noting the increasing importance of these market changes, since its inception in 2005, Diaceutics has focused on the diagnostic testing market, collating large amounts of laboratory, patient (on an anonymised and aggregated basis), claims and payor data which it uses to deliver diagnostic testing strategies to its clients. Despite the increasing importance of effective diagnostic testing, the testing market itself is currently highly fragmented and the pharmaceutical industry has varied insight into it.
The Group has amassed a set of data from over 52, 515 laboratories of which show disease volumes and 481 million de-identified patient records globally in 53 countries, insurance claims data for 464,888,990 patients and 453 million testing event data points available weekly. As part of this data collection, it has accumulated a proprietary database of laboratory capabilities across the industry.
What makes us unique?
Diaceutics’ products and services are predominantly focussed on precision testing; being tests carried out in laboratories which are used alongside a precision medicine to identify which patients will benefit most from that drug. The data that Diaceutics has amassed is being harnessed in the development of a unique platform called “DXRX”- the world’s first Diagnostic Network solution for the development and commercialization of precision medicine diagnostics.
How do we add value for our customers?
The Directors believe that DXRX will benefit its pharma clients with improved return on investment, reduced time to peak market penetration and greater revenue potential in relation to their precision therapeutic development programmes. Failure to have effective testing can significantly reduce the adoption of the relevant drug. We strive to improve testing outcomes for patients, enabling better access to the right drug at the right time.